Consolidated Statements of Cash Flows Statement (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:
Net income (loss) including noncontrolling interests in operating subsidiaries	$ (24,570)	$ 5,113
Adjustments to reconcile net income (loss) including noncontrolling interests in operating subsidiaries to net cash provided by (used in) operating activities:
Depreciation and amortization	14,552	11,774
Non-cash stock compensation	4,765	5,158
Excess tax benefits from stock-based compensation	0	709
Changes in assets and liabilities:
Accounts receivable	(7,199)	(35,508)
Prepaid expenses and other assets	(62)	(1,661)
Accounts payable and accrued expenses / costs	740	8,430
Royalties and contingent legal fees payable	(6,552)	24,228
Deferred income tax	(2,106)	0
Net cash provided by (used in) operating activities	(20,432)	16,825
Cash flows from investing activities:
Purchases of property and equipment	(96)	(241)
Purchase of available-for-sale investments	(14,234)	(97,225)
Maturities and sale of available-for-sale investments	48,632	53,262
Investments in patents/ patent rights	(987)	(4,010)
Net cash provided by (used in) investing activities	33,315	(48,214)
Cash flows from financing activities:
Payments of Dividends	(6,255)	0
Contributions from noncontrolling interests in operating subsidiary	0	1,920
Excess tax benefits from stock-based compensation	0	709
Proceeds from exercises of stock options	90	117
Net cash provided by (used in) financing activities	(6,165)	2,746
Increase (decrease) in cash and cash equivalents	6,718	(28,643)
Cash and cash equivalents, beginning	126,685	221,804
Cash and cash equivalents, ending	133,403	193,161
Patent acquisition costs included in accrued expenses	$ 15,250	$ 0